We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
A list of additional ad-hoc analyses not included in any of our standard publications.
This document (HPA-RPD-063) gives details of the study re-assessing the risk of childhood cancer among the offspring of UK women radiation workers.
How to use a cost effectiveness analysis to evaluate your digital health product.
Meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data
Lipoarabinomannan (LAM) is a potential marker of active tuberculosis (TB)
How to use routinely collected data to evaluate your digital health product.
This study aims to assess treatment outcomes among HIV–MultiDrug-Resistant -TB co-infected patients
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.